| Literature DB >> 20811498 |
Rania M Khashaba1, Mervet M Moussa, Donald J Mettenburg, Frederick A Rueggeberg, Norman B Chutkan, James L Borke.
Abstract
New polymeric calcium phosphate cement composites (CPCs) were developed. Cement powder consisting of 60 wt% tetracalcium phosphate, 30 wt% dicalcium phosphate dihydrate, and 10 wt% tricalcium phosphate was combined with either 35% w/w poly methyl vinyl ether maleic acid or polyacrylic acid to obtain CPC-1 and CPC-2. The setting time and compressive and diametral tensile strength of the CPCs were evaluated and compared with that of a commercial hydroxyapatite cement. In vitro cytotoxicity and in vivo biocompatibility of the two CPCs and hydroxyapatite cement were assessed. The setting time of the cements was 5-15 min. CPC-1 and CPC-2 showed significantly higher compressive and diametral strength values compared to hydroxyapatite cement. CPC-1 and CPC-2 were equivalent to Teflon controls after 1 week. CPC-1, CPC-2, and hydroxyapatite cement elicited a moderate to intense inflammatory reaction at 7 days which decreased over time. CPC-1 and CPC-2 show promise for orthopedic applications.Entities:
Year: 2010 PMID: 20811498 PMCID: PMC2927743 DOI: 10.1155/2010/691452
Source DB: PubMed Journal: Int J Biomater ISSN: 1687-8787
Composition of the materials used in this study.
| Material | Composition | Trade name | Manufacturer |
|---|---|---|---|
| Calcium hydrogen orthophosphate anhydrous | Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA | ||
| Calcium carbonate | Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA | ||
| Monocalcium phosphate monobasic (MCPM) | Calcium Phosphate Monobasic | Sigma Chemical Laboratories, St. Louis, MO, USA | |
| Calcium oxide | Adwic Laboratory Chemicals Cairo, Egypt | ||
| Calcium nitrate | Ca (NO3)2·4H2O FW 236.15 | Sigma Chemical Laboratories, St. Louis, MO, USA | |
| Ammonium phosphate | (NH4)2HPO4 FW 132.06 | Sigma Chemical Laboratories, St. Louis, MO, USA | |
| Polymethyl-vinyl ether-maleic anhydrate copolymer (PMVE-Ma) | Sigma Chemical Laboratories, St. Louis, MO, USA | ||
| Polyacrylic acid |
| Sigma Chemicals, St. Louis, MO, USA | |
| Bone Source Classic | Self-setting osteoconductive hydroxyapatite (HA) | Stryker Leibinger Gmb & Co. KG, Freiburg, Germany |
The Initial (I) and Final (F) setting times (in min) of hydroxyapatite cement and the two polymeric calcium phosphate cements (CPCs) (values are m e a n s ± S D; n = 5).
| Type | Initial setting time (min) | Final setting time (min) |
|---|---|---|
| Hydroxyapatite cement (Control group) | 6 ± 0.477 | 10 ± 1.40 |
| CPC-1 | 8 ± 0.95 | 15 ± 2.5 |
| CPC-2 | 5 ± 1.40 | 12 ± 1.7 |
Figure 1Histogram showing the mean initial and final setting times (in min) of hydroxyapatite cement and the two polymeric calcium phosphate cements (CPCs).
Mean compressive strength and standard deviation of hydroxyapatite cement and the two polymeric calcium phosphate cements (CPCs) [the values in parenthesis are in MPa].
| Cement Types | 30 min | 1 hrs | 4 hrs | 24 hrs | 1 week | 2 weeks | |
|---|---|---|---|---|---|---|---|
| Control Hydroxyapatite | (1.38) ± 0.18 | (1.90) ± 0.30 | (4.13) ± 0.70 | (8.08) ± 0.90 | (13.41) ± 2.10 | (17.41) ± 2.90 | |
|
| |||||||
| Calcium phosphate Cements (CPCs) | CPC-1 | (35.85) ± 5.33 | (40.42) ± 3.25 | (48.85) ± 2.75 | (71.68) ± 2.80 | (79.46) ± 3.65 | (67.12) ± 4.12 |
| CPC-2 | (72.68) ± 3.38 | (75.12) ± 3.55 | (86.05) ± 2.90 | (90.57) ± 4.09 | (78.62) ± 4.22 | (73.59) ± 3.10 | |
|
| |||||||
| LSD 5% | 4.81* | 2.36* | 2.19* | 3.30* | 4.32* | 3.22* | |
*Significant at 5% level.
Mean diametral tensile strength and standard deviation of hydroxyapatite cement and the two polymeric calcium phosphate cements (CPCs) [the value in parenthesis are in MPa].
| Cement Types | 30 min | 1 hour | 4 hrs | 24 hrs | 1 week | 2 weeks | |
|---|---|---|---|---|---|---|---|
| Control Hydroxyapatite cement | (1.56) ± 0.18 | (1.86) ± 0.30 | (1. 96) ± 0.40 | (1.36) ± 0.10 | (2.99) ± 0.80 | (1.51) ± 0.20 | |
|
| |||||||
| Calcium phosphate Cements (CPCs) | CPC-1 | (8.57) ± 2.84 | (11.43) ± 2.41 | (12.38) ± 2.04 | (13.81) ± 2.36 | (15.63) ± 2.84 | (13.77) ± 2.89 |
| CPC-2 | (12.94) ± 1.99 | (15.75) ± 1.44 | (16.31) ± 2.02 | (21.12) ± 2.99 | (17.96) ± 2.17 | (17.28) ± 2.89 | |
|
| |||||||
| LSD 5% | 2.72* | 2.72* | 2.65* | 2.63* | 2.64* | 2.84* | |
*Significant at 5% level.
Figure 2Histogram showing the mean compressive strength of hydroxyapatite cement and the two polymeric CPCs in MPa.
Figure 3Histogram showing the mean diametral strength of hydroxyapatite cement and the two polymeric CPCs in MPa
Figure 4Mitochondrial suppression induced by CPC-1, CPC-2, and commercial HA. Cytotoxicity was evaluated at three time points 24 hrs, 48 hrs and after 1 wk. Succinic dehydrogenase activity was measured and expressed as a percentage of Teflon Controls (defined as 100%). There were six replicates per condition. Different letters indicate a statistically significant difference between the materials (ANOVA, Tukey intervals α = 0.05)
Scores determined for each histological feature according to the experimental and control groups and periods of evaluation.
| ( | 7 Days | 30 Days | 90 Days | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CPC-1 | CPC-2 | HA | CPC-1 | CPC-2 | HA | CPC-1 | CPC-2 | HA | |
| Inflammatory reaction | |||||||||
| None | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 3 |
| Mild | 0 | 1 | 2 | 3 | 4 | 3 | 2 | 1 | 2 |
| Moderate | 5 | 4 | 3 | 3 | 2 | 3 | 1 | 0 | 1 |
| Severe | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrous capsule | |||||||||
| Thin | 0 | 0 | 0 | 2 | 3 | 3 | 5 | 5 | 4 |
| Thick | 6 | 6 | 6 | 4 | 3 | 3 | 1 | 1 | 2 |
| Macrophages/giant cells | |||||||||
| None | 0 | 0 | 0 | 1 | 2 | 1 | 5 | 5 | 4 |
| Mild | 4 | 5 | 5 | 4 | 4 | 4 | 1 | 1 | 2 |
| Moderate | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
Figure 5Tissue reactivity to implanted materials at 7 days. (a) this shows mild inflammatory reaction mediated by mononuclear monocytes in response to the implanted CPC-1 (arrows). (b) Implanted CPC-2 at 7 days shows a moderate inflammatory reaction mediated by mononuclear cells. (c) Implanted HA at 7 days exhibits an area of collagen degradation (arrows). (d) Example of the inflammatory reaction characterized by small dilated blood vessels and presence of giant cells observed in response to all the implanted materials (CPC1 shown) H&E X200.
Figure 6Tissue reactivity to implanted materials at 30 days. (a) Note the thick fibrous capsule (arrows) and the small dilated blood vessels in response to the implanted material (CPC-1) (arrows). (b) CPC-2 at 30 days demonstrates a thin fibrous capsule (arrows) and few macrophages adjacent to the implanted material. (c) Area showing a moderate inflammatory reaction and a thin fibrous capsule as seen in CPC-2 and HA implanted materials (CPC-2 shown). H&E X200.
Figure 7Section of tissue from area of CPC-2 implantation which demonstrates a thin fibrous capsule and a normal connective tissue denoting complete healing at 90 days. Note that this reaction is typical of all experimental implanted materials at 90 days H/E X200.